Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVA Office of Research and Development
About this trial
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treated or do not receive these different therapies. The investigators will also perform similar descriptive epidemiology for other respiratory viruses, including RSV and influenza and other infectious diseases. This first phase will critically inform feasibility and direction of the second phase, in which the investigators will use target trial emulation design to study the comparative effectiveness of therapies and vaccines for COVID-19, respiratory viruses, including RSV, and influenza, and other infectious diseases.
Eligibility criteria
Qualifiers
All Veterans aged 18 years alive and in VHA care as of January 2018.
Specific exclusion/inclusion criteria and observation periods will be further defined for each sub-study (See outcomes/publications).
Disqualifiers
VA employees who are not enrollees
Trial design
Treatments tested in this trial
- Not listed
Trial groups
400,000 Participants
are grouped into 4 trial groupsSponsors and collaborators
VA Office of Research and Development
Lead sponsor
Biomedical Advanced Research and Development Authority
Collaborator
Food and Drug Administration (FDA)
Collaborator
Source ClinicalTrials.gov